We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
Read MoreHide Full Article
IDEXX Laboratories, Inc. (IDXX - Free Report) is slated to report first-quarter 2020 results on Apr 30, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 14.29%. The company delivered a positive surprise in each of the trailing four quarters, the average beat being 10.23%.
Let's take a look at how things have shaped up prior to this announcement.
Factors at Play
IDEXX is expected to have sustained its strong earnings trajectory in the first quarter, courtesy of a global surge in Companion Animal Group (CAG) Diagnostic revenues. Although the ongoing coronavirus-induced economic crisis has affected the global animal health market, it is unlikely to have severely impacted the company’s first-quarter revenues.
From January to March, this S&P 500 stock declined 7.3%, much lower relative to the benchmark’s overall 19.6% fall. We note that the global supply chain disruption since the beginning of February impacted the stock market as a whole, and IDEXX too came into the selloff territory. However, its relative performance was better than other stocks of the index as well as the broader industry.
One major reason that might have worked in favor of IDEXX’s business during the first quarter was that there were only a few cases of pets being found COVID-19 positive globally. On Mar 13, the company itself declared that it did not see SARS-CoV-2 positive results in pets. The company noted that it evaluated thousands of canine and feline specimens during validation of a new veterinary test system for the COVID-19 virus. The specimens used for test development and validation were obtained from specimens submitted to IDEXX Reference Laboratories for PCR testing.
Through the past few quarters, the company has been witnessing solid organic revenues in CAG segment on strong contributions from consumable and reference lab as well as the growing adoption of rapid assays, and Veterinary Software, Services and Diagnostic Imaging Systems.
In the United States, IDEXX has been generating strong CAG Diagnostic recurring revenues, led by steady growth in reference lab, consumables and rapid assay sales. Continued growth in the Veterinary Software portfolio can be attributed to strength in the global catalyst install base of Cornerstone, Neo, Animana and Smart Flow systems.
International reference laboratory services are likely to have seen a robust first quarter too (without considering the global supply chain disruption issue), thanks to commercial expansion measures like the IDEXX 360 programs, and efforts to maintain momentum in international markets’ catalyst install bases.. Through the quarter, the rapid assay business is expected to have grown on the continued expansion of global SNAP Pro installed base and robust performance of its 4Dx plus franchise. Global consumable revenues are also expected to have witnessed strong growth in the to-be-reported quarter, led by increases in diagnostic test utilization and expansion of the company’s installed instrument base.
Q1 Estimates
The Zacks Consensus Estimate for first-quarter 2020 revenues is pegged at $632.4 million, indicating 9.8% rise from the prior-year quarter’s reported figure. The same for earnings is pegged at $1.23, suggesting 5.1% rise from the figure reported in the year-ago quarter.
Earnings Whispers
Per our proven model, a stock with the combination of a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and a positive Earnings ESP has a good chance of beating estimates. This is the case here as you will see below.
Earnings ESP: It has an Earnings ESP of +0.41%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: IDEXX carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Aphria Inc. carries a Zacks Rank of 2 at present and has an Earnings ESP of +35.71%.
DexCom, Inc. (DXCM - Free Report) is a Zacks #2 Ranked stock with an Earnings ESP of +143.90%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
IDEXX Laboratories, Inc. (IDXX - Free Report) is slated to report first-quarter 2020 results on Apr 30, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 14.29%. The company delivered a positive surprise in each of the trailing four quarters, the average beat being 10.23%.
Let's take a look at how things have shaped up prior to this announcement.
Factors at Play
IDEXX is expected to have sustained its strong earnings trajectory in the first quarter, courtesy of a global surge in Companion Animal Group (CAG) Diagnostic revenues. Although the ongoing coronavirus-induced economic crisis has affected the global animal health market, it is unlikely to have severely impacted the company’s first-quarter revenues.
From January to March, this S&P 500 stock declined 7.3%, much lower relative to the benchmark’s overall 19.6% fall. We note that the global supply chain disruption since the beginning of February impacted the stock market as a whole, and IDEXX too came into the selloff territory. However, its relative performance was better than other stocks of the index as well as the broader industry.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote
One major reason that might have worked in favor of IDEXX’s business during the first quarter was that there were only a few cases of pets being found COVID-19 positive globally. On Mar 13, the company itself declared that it did not see SARS-CoV-2 positive results in pets. The company noted that it evaluated thousands of canine and feline specimens during validation of a new veterinary test system for the COVID-19 virus. The specimens used for test development and validation were obtained from specimens submitted to IDEXX Reference Laboratories for PCR testing.
Through the past few quarters, the company has been witnessing solid organic revenues in CAG segment on strong contributions from consumable and reference lab as well as the growing adoption of rapid assays, and Veterinary Software, Services and Diagnostic Imaging Systems.
In the United States, IDEXX has been generating strong CAG Diagnostic recurring revenues, led by steady growth in reference lab, consumables and rapid assay sales. Continued growth in the Veterinary Software portfolio can be attributed to strength in the global catalyst install base of Cornerstone, Neo, Animana and Smart Flow systems.
International reference laboratory services are likely to have seen a robust first quarter too (without considering the global supply chain disruption issue), thanks to commercial expansion measures like the IDEXX 360 programs, and efforts to maintain momentum in international markets’ catalyst install bases.. Through the quarter, the rapid assay business is expected to have grown on the continued expansion of global SNAP Pro installed base and robust performance of its 4Dx plus franchise. Global consumable revenues are also expected to have witnessed strong growth in the to-be-reported quarter, led by increases in diagnostic test utilization and expansion of the company’s installed instrument base.
Q1 Estimates
The Zacks Consensus Estimate for first-quarter 2020 revenues is pegged at $632.4 million, indicating 9.8% rise from the prior-year quarter’s reported figure. The same for earnings is pegged at $1.23, suggesting 5.1% rise from the figure reported in the year-ago quarter.
Earnings Whispers
Per our proven model, a stock with the combination of a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and a positive Earnings ESP has a good chance of beating estimates. This is the case here as you will see below.
Earnings ESP: It has an Earnings ESP of +0.41%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: IDEXX carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Exact Sciences Corporation (EXAS - Free Report) currently carries a Zacks Rank of 2 and has an Earnings ESP of +26.79%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Aphria Inc. carries a Zacks Rank of 2 at present and has an Earnings ESP of +35.71%.
DexCom, Inc. (DXCM - Free Report) is a Zacks #2 Ranked stock with an Earnings ESP of +143.90%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>